| abstract |
The present invention provides methods for determining whether a tumor, particularly a lung tumor, is responsive to a treatment regimen comprising a platinum-based agent (e.g., cisplatin) and optionally paclitaxel. Specific Schlafen family member 11(SLFN11) fragment peptides in lung cancer cells collected from lung tumor tissue obtained from lung cancer patients were directly and accurately detected and quantified by mass spectrometry. Comparison with reference levels determines whether a cancer patient will respond positively or negatively to treatment with a chemotherapeutic drug comprising paclitaxel plus a platinum-based agent (e.g., cisplatin). |